Linqi Zhang Ph.D.

2008-present Distinguished Young Scholar of Natural Science Foundation of China
2015 China National Prize on Comprehensive Approach to Prevent and Control HIV-1/AIDS among MSM population in China
2016 Innovation Teaching Award (First Prize) on “Global Health” program for International Master of Public Health at Tsinghua University
2016 Among the Top 10 major achievements of Tsinghua Medical School
2016-present Foreign Fellow of African Academy of Sciences

Main Research Fields

Professor Zhang has devoted 30 years to studying HIV-1 pathogenesis and vaccine development, and recently expanded his research into emerging and re-emerging human viral pathogens such as Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola and Zika virus, and highly pathogenic avian influenza virus (HPAI). Using cutting-edge antibody and combinatorial antigen library techniques, Professor Zhang’s team aims to characterize protective antibody immunity in infected humans and rationally design of effective vaccines and therapeutics against the viral infection.

Selected Publications

1.Zhou P, Wang H, Fang M, Li Y, Wang H, Shi S, Li Z, Wu J, Han X, Shi X, Shang H, Zhou T, Zhang L. 2019. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. PLoS Pathog 15:e1007819.

2.Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. 2019. A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. Cell Rep 27:2593-2607.e5.

3.Wang L, Wang R, Wang L, Ben H, Yu L, Gao F, Shi X, Yin C, Zhang F, Xiang Y, Zhang L. 2019. Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody. Cell Rep 26:3360-3368.e5.

4.Li G, Jiang Y, Zhang L. 2019. HIV upsurge in China's students. Science 364:711.

5.Jia W, Channappanavar R, Zhang C, Li M, Zhou H, Zhang S, Zhou P, Xu J, Shan S, Shi X, Wang X, Zhao J, Zhou D, Perlman S, Zhang L. 2019. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. Emerg Microbes Infect 8:760-772.

6.Zuo Y, Wang P, Sun J, Guo S, Wang G, Zuo T, Fan S, Zhou P, Liang M, Shi X, Wang X, Zhang L. 2018. Complementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies. J Biol Chem 293:16503-16517.

7.Zhang S, Zhou P, Wang P, Li Y, Jiang L, Jia W, Wang H, Fan A, Wang D, Shi X, Fang X, Hammel M, Wang S, Wang X, Zhang L. 2018. Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. Cell Rep 24:441-452.

8.Wang H, Chen X, Wang D, Yao C, Wang Q, Xie J, Shi X, Xiang Y, Liu W, Zhang L. 2018. Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. J Biol Chem 293:830-846.

9.Li C, Gao F, Yu L, Wang R, Jiang Y, Shi X, Yin C, Tang X, Zhang F, Xu Z, Zhang L. 2018. A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. Cell Rep 23:1424-1434.

10.Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao GF, Xiang Y, Qiu X, Chen L, Zhang L. 2016. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep 6:25856.

11.Jin S, Ji Y, Wang Q, Wang H, Shi X, Han X, Zhou T, Shang H, Zhang L. 2016. Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection. Retrovirology 13:12.

12.Zuo T, Sun J, Wang G, Jiang L, Zuo Y, Li D, Shi X, Liu X, Fan S, Ren H, Hu H, Sun L, Zhou B, Liang M, Zhou P, Wang X, Zhang L. 2015. Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Nat Commun 6:8855.

13.Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L, Yuen KY, Zheng BJ, Wang X, Zhang L. 2014. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. Sci Transl Med 6:234ra59.